2024 |
Lozinski M, Bowden NA, Graves MC, Fay M, Day BW, Stringer BW, Tooney PA, 'ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.', Oncotarget, 15 1-18 (2024) [C1]
|
|
Nova |
2023 |
Brighi C, Puttick S, Woods A, Keall P, Tooney PA, Waddington DEJ, et al., 'Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma', International Journal of Molecular Sciences, 24 16208-16208 [C1]
|
|
|
2023 |
Maddison K, Faulkner S, Graves MC, Fay M, Bowden NA, Tooney PA, 'Vasculogenic Mimicry Occurs at Low Levels in Primary and Recurrent Glioblastoma', Cancers, 15 3922-3922 [C1]
|
|
Nova |
2022 |
Brighi C, Puttick S, Li S, Keall P, Neville K, Waddington D, et al., 'A novel semiautomated method for background activity and biological tumour volume definition to improve standardisation of 18F-FET PET imaging in glioblastoma.', EJNMMI Phys, 9 9 (2022) [C1]
|
|
Nova |
2022 |
Lozinski M, Bowden NA, Graves MC, Fay M, Day BW, Stringer BW, Tooney PA, 'Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment', Cells, 11 (2022) [C1]
Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arre... [more]
Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arrest and repair treatment-induced DNA damage. We studied the expression of DDR, its relationship with standard treatment response and patient survival, and its activation after treatment. The transcriptomic profile of DDR pathways was characterised within a cohort of isocitrate dehydrogenase (IDH) wild-type glioblastoma from The Cancer Genome Atlas (TCGA) and 12 patient-derived glioblastoma cell lines. The relationship between DDR expression and patient survival and cell line response to temozolomide (TMZ) or radiation therapy (RT) was assessed. Finally, the expression of 84 DDR genes was examined in glioblastoma cells treated with TMZ and/or RT. Although distinct DDR cluster groups were apparent in the TCGA cohort and cell lines, no significant differences in OS and treatment response were observed. At the gene level, the high expression of ATP23, RAD51C and RPA3 independently associated with poor prognosis in glioblastoma patients. Finally, we observed a substantial upregulation of DDR genes after treatment with TMZ and/or RT, particularly in RTtreated glioblastoma cells, peaking within 24 h after treatment. Our results confirm the potential influence of DDR genes in patient outcome. The observation of DDR genes in response to TMZ and RT gives insight into the global response of DDR pathways after adjuvant treatment in glioblastoma, which may have utility in determining DDR targets for inhibition.
|
|
Nova |
2022 |
Song AJ, Ding K, Alnahhas I, Laperriere NJ, Perry J, Mason WP, et al., 'Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial (vol 3, vdab153, 2021)', NEURO-ONCOLOGY ADVANCES, 4 (2022)
|
|
|
2021 |
Lozinski M, Bowden NA, Graves MC, Fay M, Tooney PA, 'DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets', CELLULAR ONCOLOGY, 44 961-981 (2021) [C1]
|
|
Nova |
2021 |
Song AJ, Ding K, Alnahhas I, Laperriere NJ, Perry J, Mason WP, et al., 'Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial', Neuro-Oncology Advances, 3 (2021) [C1]
Background: Lymphopenia may lead to worse outcomes for glioblastoma patients. This study is a secondary analysis of the CCTG CE.6 trial evaluating the impact of chemotherapy and r... [more]
Background: Lymphopenia may lead to worse outcomes for glioblastoma patients. This study is a secondary analysis of the CCTG CE.6 trial evaluating the impact of chemotherapy and radiation on lymphopenia, and effects of lymphopenia on overall survival (OS). Methods: CCTG CE.6 randomized elderly glioblastoma patients (= 65 years) to short-course radiation alone (RT) or short-course radiation with temozolomide (RT + TMZ). Lymphopenia (mild-moderate: Grade 1-2; severe: Grade 3-4) was defined per CTCAE v3.0, and measured at baseline, 1 week and 4 weeks post-RT. Preselected key factors for analysis included age, sex, ECOG, resection extent, MGMT methylation, Mini-Mental State Examination, and steroid use. Multinomial logistic regression and multivariable Cox regression models were used to identify lymphopenia-associated factors and association with survival. Results: Five hundred and sixty-two patients were analyzed (281 RT vs 281 RT+TMZ). At baseline, both arms had similar rates of mild-moderate (21.4% vs 21.4%) and severe (3.2% vs 2.9%) lymphopenia. However, at 4 weeks post-RT, RT+TMZ was more likely to develop lymphopenia (mild-moderate: 27.9% vs 18.2%; severe: 9.3% vs 1.8%; p<0.001). Developing any lymphopenia post-RT was associated with baseline lymphopenia (P <. 001). Baseline lymphopenia (hazard ratio [HR] 1.3) was associated with worse OS (HR: 1.30, 95% confidence interval [CI] 1.05-1.62; P =. 02), regardless of MGMT status. Conclusions: Development of post-RT lymphopenia is associated with addition of TMZ and baseline lymphopenia and not with RT alone in patients treated with short-course radiation. However, regardless of MGMT status, only baseline lymphopenia is associated with worse OS, which may be considered as a prognostic biomarker for elderly glioblastoma patients.
|
|
|
2021 |
Maddison K, Graves MC, Bowden NA, Fay M, Vilain RE, Faulkner S, Tooney PA, 'Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma', Oncotarget, 12 2177-2187 (2021) [C1]
Immunotherapies targeting tumour-infiltrating lymphocytes (TILs) that express the immune checkpoint molecule programmed cell death-1 (PD-1) have shown promise in preclinical gliob... [more]
Immunotherapies targeting tumour-infiltrating lymphocytes (TILs) that express the immune checkpoint molecule programmed cell death-1 (PD-1) have shown promise in preclinical glioblastoma models but have had limited success in clinical trials. To assess when glioblastoma is most likely to benefit from immune checkpoint inhibitors we determined the density of TILs in primary and recurrent glioblastoma. Thirteen cases of matched primary and recurrent glioblastoma tissue were immunohistochemically labelled for CD3, CD8, CD4 and PD-1, and TIL density assessed. CD3+ TILs were observed in all cases, with the majority of both primary (69.2%) and recurrent (61.5%) tumours having low density of TILs present. CD8+ TILs were observed at higher densities than CD4+ TILs in both tumour groups. PD-1+ TILs were sparse and present in only 25% of primary and 50% of recurrent tumours. Quantitative analysis of TILs demonstrated significantly higher CD8+ TIL density at recurrence (p = 0.040). No difference was observed in CD3+ (p = 0.191), CD4+ (p = 0.607) and PD-1+ (p = 0.070) TIL density between primary and recurrent groups. This study shows that TILs are present at low densities in both primary and recurrent glioblastoma. Furthermore, PD-1+ TILs were frequently absent, which may provide evidence as to why anti-PD-1 immunotherapy trials have been largely unsuccessful in glioblastoma.
|
|
Nova |
2021 |
Maishman T, Sheikh H, Boger P, Kelly J, Cozens K, Bateman A, et al., 'A Phase II Study of Biodegradable Stents Plus Palliative Radiotherapy in Oesophageal Cancer', Clinical Oncology, 33 e225-e231 (2021) [C1]
Aims: Self-expanding metal stents provide rapid improvement of dysphagia in oesophageal cancer but are associated with complications. The aim of the present study was to test the ... [more]
Aims: Self-expanding metal stents provide rapid improvement of dysphagia in oesophageal cancer but are associated with complications. The aim of the present study was to test the effectiveness of an alternative treatment of combining biodegradable stents with radiotherapy. Materials and methods: A Simon two-stage single-arm prospective phase II trial design was used to determine the efficacy of biodegradable stents plus radiotherapy in patients with dysphagia caused by oesophagus cancer who were unsuitable for radical treatment. Fourteen patients were recruited and data from 12 were included in the final analyses. Results: Five of 12 patients met the primary end point: one stent-related patient death; four further interventions for dysphagia within 16 weeks of stenting (41.7%, 95% confidence interval 15.2¿72.3%). The median time to a 10-point deterioration of quality of life was 2.7 weeks. Nine patients died within 52 weeks of registration. The median time to death from any cause was 15.0 weeks (95% confidence interval 9.6¿not reached). Conclusion: The high re-intervention observed, which met the pre-defined early stopping criteria, meant that the suggested alternative treatment was not sufficiently effective to be considered for a larger scale trial design. Further work is needed to define the place of biodegradable stents in the management of malignant oesophageal strictures.
|
|
|
2020 |
Climans SA, Brandes AA, Cairncross JG, Ding K, Fay M, Laperriere N, et al., 'Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients', Journal of Neuro-Oncology, 149 65-71 (2020) [C1]
Introduction: Tumor-related epilepsy may respond to chemotherapy. In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomi... [more]
Introduction: Tumor-related epilepsy may respond to chemotherapy. In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone. Seizure outcomes were not reported. Methods: We performed an unplanned secondary analysis of this trial¿s data. The trial design has been previously reported. Seizures were recorded by clinicians as adverse events and by patients in quality of life questionnaires. A Chi-square test of seizure rates between the two groups (a = 0.05) and a Kaplan¿Meier estimator of time-to-first self-reported seizure were planned. Results: Almost all patients were followed until they died. In the radiotherapy alone group, 68 patients (24%) had a documented or self-reported seizure versus 83 patients (30%) in the temozolomide plus radiotherapy group, Chi-square analysis showed no difference (p = 0.15). Patients receiving radiotherapy alone tended to develop seizures earlier than those receiving temozolomide plus radiotherapy (p = 0.054). Patients with seizures had shorter overall survival than those without seizures (hazard ratio 1.24, p = 0.02). Conclusions: This study was not powered to detect differences in seizure outcomes, but temozolomide seemed to have minimal impact on seizure control in elderly patients with glioblastoma. Clinical Trial Registration: NCT00482677 2007-06-05.
|
|
Nova |
2018 |
Tam L, Garvey G, Meiklejohn J, Martin J, Adams J, Walpole E, et al., 'Exploring positive survivorship experiences of indigenous Australian cancer patients', International Journal of Environmental Research and Public Health, 15 (2018) [C1]
|
|
Nova |
2018 |
Martinage G, Hong AM, Fay M, Thachil T, Roos D, Williams N, et al., 'Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance', RADIATION ONCOLOGY, 13 (2018) [C1]
|
|
Nova |
2017 |
Head RJ, Fay MF, Cosgrove L, Y C Fung K, Rundle-Thiele D, Martin JH, 'Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma', Cancer Biology and Therapy, 18 917-926 (2017) [C1]
Glioblastoma is a lethal form of brain tumour usually treated by surgical resection followed by radiotherapy and an alkylating chemotherapeutic agent. Key to the success of this m... [more]
Glioblastoma is a lethal form of brain tumour usually treated by surgical resection followed by radiotherapy and an alkylating chemotherapeutic agent. Key to the success of this multimodal approach is maintaining apoptotic sensitivity of tumour cells to the alkylating agent. This initial treatment likely establishes conditions contributing to development of drug resistance as alkylating agents form the O6-methylguanine adduct. This activates the mismatch repair (MMR) process inducing apoptosis and mutagenesis. This review describes key juxtaposed drivers in the balance between alkylation induced mutagenesis and apoptosis. Mutations in MMR genes are the probable drivers for alkylation based drug resistance. Critical to this interaction are the dose-response and temporal interactions between adduct formation and MMR mutations. The precision in dose interval, dose-responses and temporal relationships dictate a role for alkylating agents in either promoting experimental tumour formation or inducing tumour cell death with chemotherapy. Importantly, this resultant loss of chemotherapeutic selective pressure provides opportunity to explore novel therapeutics and appropriate combinations to minimise alkylation based drug resistance and tumour relapse.
|
|
Nova |
2017 |
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al., 'Short-course radiation plus temozolomide in elderly patients with glioblastoma', New England Journal of Medicine, 376 1027-1037 (2017) [C1]
|
|
Nova |
2016 |
Garvey G, Cunningham J, He VY, Janda M, Baade P, Sabesan S, et al., 'Health-related quality of life among Indigenous Australians diagnosed with cancer', QUALITY OF LIFE RESEARCH, 25 1999-2008 (2016) [C1]
|
|
Nova |
2016 |
Cheng M, Fay M, Steinke K, 'Percutaneous CT-guided thermal ablation as salvage therapy for recurrent non-small cell lung cancer after external beam radiotherapy: A retrospective study', International Journal of Hyperthermia, 32 316-323 (2016) [C1]
Abstract: Purpose: The aim of this study was to evaluate radiofrequency ablation (RFA) and microwave ablation (MWA) as a viable salvage option for patients with locally recurrent ... [more]
Abstract: Purpose: The aim of this study was to evaluate radiofrequency ablation (RFA) and microwave ablation (MWA) as a viable salvage option for patients with locally recurrent non-small cell lung cancer (NSCLC) after radiotherapy. Materials and methods: This retrospective study was conducted on patients who had received thermal ablation for recurrent NSCLC post-curative radiotherapy. Medical records and follow-up imaging with computed tomography (CT) and PET-CT were analysed to determine time to local progression (TTLP) and overall survival (OS). TTLP was determined according to the modified RECIST criteria. Results: Twelve patients, mean age 71 ± 7 years, received 17 thermal ablation sessions, with RFA performed for four lesions and MWA for 13. Nine tumours were squamous cell cancers (SCC) and eight were adenocarcinomas. Eleven tumours had recurred post-external beam radiation and one post-stereotactic body radiation therapy. Mean tumour size was 34.2 ± 12.8 mm, tumour stages prior to radiotherapy were Ia (2), Ib (3), IIa (4), IIb (1) and III (2). Follow-up period was 19 ± 11 months. Overall median TTLP was 14 months (95% CI: 8, 19), and median OS was 35 months (95% CI: 12, 58). Mean TTLP for tumours <30 mm was 23 months and for tumours >30 mm 14 months (p = 0.20). Recurrence rates reduced from 50% after initial ablation to 20% with a second ablation. Complication rate for pneumothorax requiring intervention was 17%. Conclusion: Both RFA and MWA ablation prolonged local tumour control with minimal morbidity in this study group of recurrent NSCLC after radiotherapy.
|
|
Nova |
2016 |
Fay MF, Head R, Sminia P, Dowson N, Cosgrove L, Rose SE, Martin JH, 'Valproate in Adjuvant Glioblastoma Treatment', JOURNAL OF CLINICAL ONCOLOGY, 34 3105-+ (2016)
|
|
|
2015 |
Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y, Rose S, 'Hypoxia Imaging in Gliomas With F-18-Fluoromisonidazole PET: Toward Clinical Translation', SEMINARS IN NUCLEAR MEDICINE, 45 136-150 (2015)
|
|
|
2015 |
Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, et al., 'Increasing feasibility and utility of F-18-FDOPA PET for the management of glioma', NUCLEAR MEDICINE AND BIOLOGY, 42 788-795 (2015)
|
|
|
2015 |
Puttick S, Bell C, Dowson N, Rose S, Fay M, 'PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma', DRUG DISCOVERY TODAY, 20 306-317 (2015)
|
|
|
2015 |
Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Khatun M, Barras M, 'The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'', SUPPORTIVE CARE IN CANCER, 23 71-78 (2015) [C1]
|
|
Nova |
2015 |
Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, et al., 'EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study.', Mol Imaging, 14 7290201500008 (2015)
|
|
|
2015 |
Fay M, Head R, Martin J, 'Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?', Journal of Neuro-Oncology, (2015) [C1]
Personalized medicine has been helpful for drug development in diseases with single and relatively stable gene mutations. The benefit for complex solid tumours with heterogeneous ... [more]
Personalized medicine has been helpful for drug development in diseases with single and relatively stable gene mutations. The benefit for complex solid tumours with heterogeneous and changing genetic profiles is less clear. Whether it is efficient to continue diverting resources from combined biological and pharmacological approaches to trial new and existing genetic ¿targeted therapies¿ for brain tumours is unknown but of developing concern in resource constrained environments.
|
|
Nova |
2015 |
Rundle-Thiele D, Day B, Stringer B, Fay M, Martin J, Jeffree RL, et al., 'Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: Importance of analytical method', Journal of Medical Radiation Sciences, 62 92-98 (2015) [C1]
Introduction: Accurate knowledge of O6-methylguanine methyltransferase (MGMT) gene promoter subtype in patients with glioblastoma (GBM) is important for treatment. However, this t... [more]
Introduction: Accurate knowledge of O6-methylguanine methyltransferase (MGMT) gene promoter subtype in patients with glioblastoma (GBM) is important for treatment. However, this test is not always available. Pre-operative diffusion MRI (dMRI) can be used to probe tumour biology using the apparent diffusion coefficient (ADC); however, its ability to act as a surrogate to predict MGMT status has shown mixed results. We investigated whether this was due to variations in the method used to analyse ADC. Methods: We undertook a retrospective study of 32 patients with GBM who had MGMT status measured. Matching pre-operative MRI data were used to calculate the ADC within contrast enhancing regions of tumour. The relationship between ADC and MGMT was examined using two published ADC methods. Results: A strong trend between a measure of 'minimum ADC' and methylation status was seen. An elevated minimum ADC was more likely in the methylated compared to the unmethylated MGMT group (U = 56, P = 0.0561). In contrast, utilising a two-mixture model histogram approach, a significant reduction in mean measure of the 'low ADC' component within the histogram was associated with an MGMT promoter methylation subtype (P < 0.0246). Conclusion: This study shows that within the same patient cohort, the method selected to analyse ADC measures has a significant bearing on the use of that metric as a surrogate marker of MGMT status. Thus for dMRI data to be clinically useful, consistent methods of data analysis need to be established prior to establishing any relationship with genetic or epigenetic profiling.
|
|
Nova |
2015 |
Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, et al., 'The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells', Journal of Neuro-Oncology, 122 263-271 (2015) [C1]
Glioblastoma multiforme (GBM) has nearly uniformly fatal with a median survival of less than 2¿years. While there have not been any novel anti-GBM therapeutics approved for many y... [more]
Glioblastoma multiforme (GBM) has nearly uniformly fatal with a median survival of less than 2¿years. While there have not been any novel anti-GBM therapeutics approved for many years, there has been the gradual accumulation of clinical data suggesting that the widely used anti-convulsant agent, valproic acid (VPA) may significantly prolong survival in GBM patients. This pre-clinical study aimed to determine the potential clinical utility of VPA in the treatment of GBM. Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation. At clinically achievable concentrations, VPA was shown to be effective as a monotherapy agent in the five primary lines tested. VPA was then used as a sensitizing agent to in vitro radiation and showed significant augmentation of in vitro irradiation therapy. In addition, when VPA, radiation and temozolomide were combined an additive, rather than synergistic effect was noted. Gene expression profiling demonstrated close clustering of triple treated cells with VPA mono-treated cells while untreated cells clustered closer with TMZ-irradiation dual treated cells. These microarray data suggest a dominant role of VPA at the gene expression level when combining these different treatment options. Moreover, in an in vivo tumor transplantation model, we were able to demonstrate an increase in animal survival when cells were pre-treated with irradiation-VPA and when triple treated. These findings provide a significant rationale for the investigation of VPA in the treatment of GBM patients.
|
|
Nova |
2015 |
Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, et al., 'EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study', MOLECULAR IMAGING, 14 385-+ (2015)
|
|
|
2014 |
Bell C, Rose S, Puttick S, Pagnozzi A, Poole CM, Gal Y, et al., 'Dual acquisition of F-18-FMISO and F-18-FDOPA', PHYSICS IN MEDICINE AND BIOLOGY, 59 3925-3949 (2014) [C1]
|
|
|
2014 |
Bell C, Pannek K, Fay M, Thomas P, Bourgeat P, Salvado O, et al., 'Distance informed Track-Weighted Imaging (diTWI): A framework for sensitising streamline information to neuropathology', NEUROIMAGE, 86 60-66 (2014) [C1]
|
|
|
2014 |
Dowson N, Thomas P, Fay M, Jeffree RL, Gal Y, Bourgeat P, et al., 'Early prediction of treatment response in advanced gliomas with F-18-DOPA positron-emission tomography', CURRENT ONCOLOGY, 21 E172-E178 (2014)
|
|
|
2014 |
Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Barras M, 'Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches', SUPPORTIVE CARE IN CANCER, 22 1113-1119 (2014)
|
|
|
2014 |
Carroll JP, Protani MM, Nguyen L, Cheng ME, Fay M, Saleem M, et al., 'Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.', Med Oncol, 31 881-881 (2014)
|
|
|
2014 |
Fay MF, Martin JH, Rose S, 'New imaging techniques for more effective treatment in glioblastoma', Internal Medicine Journal, 44 5-6 (2014) [C3]
|
|
|
2014 |
Gal Y, Dowson N, Bourgeat P, Salvado O, Thomas P, Fay M, et al., 'Amorphous Regions-of-Interest Projection Method for Simplified Longitudinal Comparison of Dynamic Regions in Cancer Imaging', IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 61 264-272 (2014) [C1]
|
|
|
2013 |
Rose S, Fay M, Thomas P, Bourgeat P, Dowson N, Salvado O, et al., 'Correlation of MRI-Derived Apparent Diffusion Coefficients in Newly Diagnosed Gliomas with [F-18]-Fluoro-L-Dopa PET: What Are We Really Measuring with Minimum ADC?', AMERICAN JOURNAL OF NEURORADIOLOGY, 34 758-764 (2013)
|
|
|
2013 |
Goergen SK, Pool FJ, Turner TJ, Grimm JE, Appleyard MN, Crock C, et al., 'Evidence-based guideline for the written radiology report: Methods, recommendations and implementation challenges', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 57 1-7 (2013)
|
|
|
2013 |
Bettington CS, Tripcony L, Bryant G, Hickey B, Pratt G, Fay M, 'A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 57 105-112 (2013)
|
|
|
2013 |
Fay M, Poole CM, Pratt G, 'Recent advances in radiotherapy for thoracic tumours', JOURNAL OF THORACIC DISEASE, 5 S551-S555 (2013)
|
|
|
2012 |
Fay M, Thomas P, 'FUNCTIONAL IMAGING USING PET AND RADIOTHERAPY PLANNING', CANCER FORUM, 36 77-79 (2012)
|
|
|
2011 |
Martin JM, Brett R, Blyth J, Morrison S, Bryant D, Plank A, et al., 'Dosimetric effect of external beam planning preceding combined high-dose-rate brachytherapy of the prostate', BRACHYTHERAPY, 10 474-478 (2011) [C1]
|
|
|
2011 |
Bettington C, Tripcony L, Hickey B, Bryant G, Pratt G, Fay M, 'A RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR TWO DIFFERENT RADIOTHERAPY FRACTIONATION SCHEDULES GIVEN IN THE SAME OVERALL TIME FOR LIMITED STAGE SMALL CELL LUNG CANCER', JOURNAL OF THORACIC ONCOLOGY, 6 S6-S6 (2011) |
|
|
2011 |
Rassam LJ, Sinhal NP, Mackenzie H, Bowman RV, Fong KM, Yang IA, et al., 'THE LUNG CANCER JOURNEY - A REVIEW FROM THE PRINCE CHARLES HOSPITAL PULMONARY MALIGNANCY UNIT', JOURNAL OF THORACIC ONCOLOGY, 6 S36-S36 (2011) |
|
|
2011 |
Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J, 'Pitfalls of using estimations of glomerular filtration rate in an intensive care population', Internal Medicine Journal, 41 537-543 (2011) [C1]
|
|
|
2010 |
Dowson N, Bourgeat P, Rose S, Daglish M, Smith J, Fay M, et al., 'Joint factor and kinetic analysis of dynamic FDOPA PET scans of brain cancer patients', Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 6362 LNCS 185-192 (2010)
Kinetic analysis is an essential tool of Positron Emission Tomography image analysis. However it requires a pure tissue time activity curve (TAC) in order to calculate the system ... [more]
Kinetic analysis is an essential tool of Positron Emission Tomography image analysis. However it requires a pure tissue time activity curve (TAC) in order to calculate the system parameters. Pure tissue TACs are particularly difficult to obtain in the brain as the low resolution of PET means almost all voxels are a mixture of tissues. Factor analysis explicitly accounts for mixing but is an underdetermined problem that can give arbitrary results. A joint factor and kinetic analysis is proposed whereby factor analysis explicitly accounts for mixing of tissues. Hence, more meaningful parameters are obtained by the kinetic models, which also ensure a less ambiguous solution to the factor analysis. The method was tested using a cylindrical phantom and the 18F-DOPA data of a brain cancer patient. © 2010 Springer-Verlag.
|
|
|
2010 |
Martin JM, Gorayski P, Zwahlen D, Fay M, Keller J, Millar J, 'IS RADIOTHERAPY A GOOD ADJUVANT STRATEGY FOR MEN WITH A HISTORY OF CRYPTORCHISM AND STAGE I SEMINOMA?', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76 65-70 (2010) [C1]
|
|
|
2010 |
Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J, 'Pitfalls of using estimations of glomerular filtration rate in an intensive care population', Internal Medicine Journal, (2010)
|
|
|
2010 |
Martin JH, Fay MF, 'Surrogate end-points in clinical practice: are we providing worse care?', INTERNAL MEDICINE JOURNAL, 40 395-398 (2010)
|
|
|
2009 |
de Winton E, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, et al., 'The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer', BRITISH JOURNAL OF CANCER, 100 693-700 (2009)
|
|
|
2009 |
Martin JH, Fay MF, Ungerer JP, 'eGFR - use beyond the evidence', MEDICAL JOURNAL OF AUSTRALIA, 190 197-199 (2009)
|
|
|
2009 |
Khamly KK, Thursfield VJ, Fay M, Desai J, Toner GC, Choong PFM, et al., 'Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood', INTERNATIONAL JOURNAL OF CANCER, 125 426-431 (2009)
|
|
|
2007 |
Fogarty GB, Cassumbhoy R, Martin JM, Fay M, Ainslie J, 'Technique for axillary radiotherapy using computer-assisted planning for high-risk skin cancer', AUSTRALASIAN RADIOLOGY, 51 267-275 (2007)
|
|
|
2005 |
Fay M, Tan A, Fisher R, Mac Manus M, Wirth A, Ball D, 'Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 61 1355-1363 (2005)
|
|
|
2001 |
Martin J, Fay MF, 'Cytochrome P450 drug interactions: are they clinically relevant?', Australian Prescriber, 24 10-12 (2001) |
|
|
2001 |
Martin JH, 'Cytochrome P450 drug interactions: are they clinically relevent?', Australian Prescriber, 24 10-12 (2001)
|
|
|
2001 |
Martin JH, Fay MF, 'Capecitabine', Current Therapeutics, 42 49-51 (2001)
|
|
|
2001 |
Fay M, 'The Dana-Farber Cancer Institute', The Lancet Oncology, 2 121-121 (2001)
|
|
|
2000 |
Fay M, 'Rates and risks', The Lancet Oncology, 1 62-62 (2000)
|
|
|
2000 |
Fay M, 'Improving and maintaining human health', The Lancet Oncology, 1 250-250 (2000)
|
|
|
1999 |
Fay MF, Nicholls MG, Richards AM, 'A man with severe, transient hypertension due to acute renal infarction', JOURNAL OF HUMAN HYPERTENSION, 13 343-344 (1999)
|
|
|